Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Italy Fines Apple €98.6 Million Over App Store Dominance 
NEW YORK, Oct. 11, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the company has been selected to present at the 2016 Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology (AAO) Annual Meeting being held in Chicago, Illinois, on Thursday, October 13, 2016. Dr. Jason Slakter, Chief Executive Officer of Ohr, will be making the presentation.
| Presentation Details (Posterior Segment Company Showcase) | ||
| Date: | Thursday, October 13, 2016 | |
| Time: | 12:10pm Central Time | |
| Location: | Hyatt Regency, 151 East Wacker Drive, Chicago IL | |
About the Ophthalmology Innovation Summit
The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors, and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities – while showcasing the most promising ophthalmic companies. For more information, please go to http://ois.net/ois-aao-2016/.
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being evaluated in combination with anti-VEGF injections in a Phase 3 clinical program for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
